Journal article
CASSETTE-clindamycin adjunctive therapy for severe Staphylococcus aureus treatment evaluation: Study protocol for a randomised controlled trial
R Dotel, SYC Tong, A Bowen, JN Nelson, MVN O'sullivan, AJ Campbell, BJ McMullan, PN Britton, JR Francis, DP Eisen, O Robinson, L Manning, JS Davis
Trials | BMC | Published : 2019
Open access
Abstract
Background: Exotoxins are important virulence factors in Staphylococcus aureus. Clindamycin, a protein synthesis inhibitor antibiotic, is thought to limit exotoxin production and improve outcomes in severe S. aureus infections. However, randomised prospective data to support this are lacking. Methods: An open-label, multicentre, randomised controlled trial (RCT) will compare outcome differences in severe S. aureus infection between standard treatment (flucloxacillin/cefazolin in methicillin-susceptible S. aureus; and vancomycin/daptomycin in methicillin-resistant S. aureus) and standard treatment plus an additional clindamycin given for 7 days. We will include a minimum of 60 participants (b..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
The study is supported by Australian National Health and Medical Research Council (NHMRC) ID GNT1131932. SYCT is a NHMRC Career Development Fellow (#1145033), AB is a NHMRC Early Career Fellow (#1088735), and JSD is a NHMRC Career Development Fellow (#1083105).